Browsing by title

Now showing items 1571-1590 of 3939

    • Haemato-oncology patients’ perceptions of health-related quality of life after critical illness: A qualitative phenomenological study 

      O’Gara, G; Tuddenham, S; Pattison, N (Elsevier BV, 2018-02)

    • Haemophagocytic lymphohistiocytosis as a consequence of untreated B-cell chronic lymphocytic leukaemia 

      Bailey, C; Dearden, C; Ardeshna, K

    • Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(aEuro) 

      Robak, T; Matutes, E; Catovsky, D; Zinzani, PL; Buske, C; Comm, ESMOG (OXFORD UNIV PRESS, 2015-09)

    • Harnessing the tumour-derived cytokine, CSF-1, to co-stimulate T-cell growth and activation 

      Lo, ASY; Taylor, JR; Farzaneh, F; Kemeny, DM; Dibb, NJ; Maher, J (PERGAMON-ELSEVIER SCIENCE LTD, 2008-03)
      Aberrant growth factor production is a prevalent mechanism in tumourigenesis. If T-cells responded positively to a cancer-derived cytokine, this might result in selective enhancement of function within the tumour ...

    • Health economic impact of liquid biopsies in cancer management. 

      IJzerman, MJ; Berghuis, AMS; de Bono, JS; Terstappen, LWMM (2018-12)
      INTRODUCTION:Liquid biopsies (LBs) are referred to as the sampling and analysis of non-solid tissue, primarily blood, as a diagnostic and monitoring tool for cancer. Because LBs are largely non-invasive, they are a less-costly ...

    • Health-related quality of life among cancer patients in their last year of life: results from the PROFILES registry. 

      Raijmakers, NJH; Zijlstra, M; van Roij, J; Husson, O; Oerlemans, S; van de Poll-Franse, LV (2018-10)
      PURPOSE:The aim of this study was to assess health-related quality of life (HRQoL) in the last year of life of cancer patients stratified by four periods of time before death. PATIENTS AND METHODS:Between 2008 and 2015, ...

    • Health-related quality of life around the time of diagnosis in patients with bladder cancer. 

      Yu, EY-W; Nekeman, D; Billingham, LJ; James, ND; Cheng, KK; Bryan, RT; Wesselius, A; Zeegers, MP (2019-12)
      OBJECTIVES:To quantify the health-related quality of life (HRQoL) of patients with bladder cancer around the time of diagnosis and to test the hypotheses of a two-factor model for the HRQoL questionnaire QLQ-C30. METHODS:From ...

    • Health-related quality of life in sarcoma patients: enhancing personalized medicine. 

      van der Graaf, W

    • Health-related quality of life results from the phase III CheckMate 067 study. 

      Schadendorf, D; Larkin, J; Wolchok, J; Hodi, FS; Chiarion-Sileni, V; Gonzalez, R; Rutkowski, P; Grob, J-J; Cowey, CL; Lao, C; Wagstaff, J; Callahan, MK; Postow, MA; Smylie, M; Ferrucci, PF; Dummer, R; Hill, A; Taylor, F; Sabater, J; Walker, D; Kotapati, S; Abernethy, A; Long, GV (2017-09)
      BACKGROUND:Nivolumab, a monoclonal antibody of immune checkpoint programmed death 1 on T cells (PD-1), combined with ipilimumab, an immune checkpoint cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor, as ...

    • Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. 

      Brahmer, JR; Rodríguez-Abreu, D; Robinson, AG; Hui, R; Csőszi, T; Fülöp, A; Gottfried, M; Peled, N; Tafreshi, A; Cuffe, S; O'Brien, M; Rao, S; Hotta, K; Zhang, J; Lubiniecki, GM; Deitz, AC; Rangwala, R; Reck, M (2017-12)
      BACKGROUND:In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer ...

    • HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients 

      Li, Z; Zhou, L; Prodromou, C; Savic, V; Pearl, LH (Elsevier BV, 2017-06)

    • Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. 

      Qian, F; Wang, S; Mitchell, J; McGuffog, L; Barrowdale, D; Leslie, G; Oosterwijk, JC; Chung, WK; Evans, DG; Engel, C; Kast, K; Aalfs, CM; Adank, MA; Adlard, J; Agnarsson, BA; Aittomäki, K; Alducci, E; Andrulis, IL; Arun, BK; Ausems, MGEM; Azzollini, J; Barouk-Simonet, E; Barwell, J; Belotti, M; Benitez, J; Berger, A; Borg, A; Bradbury, AR; Brunet, J; Buys, SS; Caldes, T; Caligo, MA; Campbell, I; Caputo, SM; Chiquette, J; Claes, KBM; Margriet Collée, J; Couch, FJ; Coupier, I; Daly, MB; Davidson, R; Diez, O; Domchek, SM; Donaldson, A; Dorfling, CM; Eeles, R; Feliubadaló, L; Foretova, L; Fowler, J; Friedman, E; Frost, D; Ganz, PA; Garber, J; Garcia-Barberan, V; Glendon, G; Godwin, AK; Gómez Garcia, EB; Gronwald, J; Hahnen, E; Hamann, U; Henderson, A; Hendricks, CB; Hopper, JL; Hulick, PJ; Imyanitov, EN; Isaacs, C; Izatt, L; Izquierdo, Á; Jakubowska, A; Kaczmarek, K; Kang, E; Karlan, BY; Kets, CM; Kim, S-W; Kim, Z; Kwong, A; Laitman, Y; Lasset, C; Hyuk Lee, M; Won Lee, J; Lee, J; Lester, J; Lesueur, F; Loud, JT; Lubinski, J; Mebirouk, N; Meijers-Heijboer, HEJ; Meindl, A; Miller, A; Montagna, M; Mooij, TM; Morrison, PJ; Mouret-Fourme, E; Nathanson, KL; Neuhausen, SL; Nevanlinna, H; Niederacher, D; Nielsen, FC; Nussbaum, RL; Offit, K; Olah, E; Ong, K-R; Ottini, L; Park, SK; Peterlongo, P; Pfeiler, G; Phelan, CM; Poppe, B; Pradhan, N; Radice, P; Ramus, SJ; Rantala, J; Robson, M; Rodriguez, GC; Schmutzler, RK; Hutten Selkirk, CG; Shah, PD; Simard, J; Singer, CF; Sokolowska, J; Stoppa-Lyonnet, D; Sutter, C; Yen Tan, Y; Teixeira, RM; Teo, SH; Terry, MB; Thomassen, M; Tischkowitz, M; Toland, AE; Tucker, KM; Tung, N; van Asperen, CJ; van Engelen, K; van Rensburg, EJ; Wang-Gohrke, S; Wappenschmidt, B; Weitzel, JN; Yannoukakos, D; GEMO Study Collaborators; HEBON; EMBRACE; Greene, MH; Rookus, MA; Easton, DF; Chenevix-Trench, G; Antoniou, AC; Goldgar, DE; Olopade, OI; Rebbeck, TR; Huo, D (2019-04)
      BACKGROUND:BRCA1/2 mutations confer high lifetime risk of breast cancer, although other factors may modify this risk. Whether height or body mass index (BMI) modifies breast cancer risk in BRCA1/2 mutation carriers remains ...

    • Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. 

      Zhang, B; Shu, X-O; Delahanty, RJ; Zeng, C; Michailidou, K; Bolla, MK; Wang, Q; Dennis, J; Wen, W; Long, J; Li, C; Dunning, AM; Chang-Claude, J; Shah, M; Perkins, BJ; Czene, K; Darabi, H; Eriksson, M; Bojesen, SE; Nordestgaard, BG; Nielsen, SF; Flyger, H; Lambrechts, D; Neven, P; Wildiers, H; Floris, G; Schmidt, MK; Rookus, MA; van den Hurk, K; de Kort, WLAM; Couch, FJ; Olson, JE; Hallberg, E; Vachon, C; Rudolph, A; Seibold, P; Flesch-Janys, D; Peto, J; Dos-Santos-Silva, I; Fletcher, O; Johnson, N; Nevanlinna, H; Muranen, TA; Aittomäki, K; Blomqvist, C; Li, J; Humphreys, K; Brand, J; Guénel, P; Truong, T; Cordina-Duverger, E; Menegaux, F; Burwinkel, B; Marme, F; Yang, R; Surowy, H; Benitez, J; Zamora, MP; Perez, JIA; Cox, A; Cross, SS; Reed, MWR; Andrulis, IL; Knight, JA; Glendon, G; Tchatchou, S; Sawyer, EJ; Tomlinson, I; Kerin, MJ; Miller, N; Chenevix-Trench, G; kConFab Investigators, Australian Ovarian Study Group; Haiman, CA; Henderson, BE; Schumacher, F; Marchand, LL; Lindblom, A; Margolin, S; Hooning, MJ; Martens, JWM; Tilanus-Linthorst, MMA; Collée, JM; Hopper, JL; Southey, MC; Tsimiklis, H; Apicella, C; Slager, S; Toland, AE; Ambrosone, CB; Yannoukakos, D; Giles, GG; Milne, RL; McLean, C; Fasching, PA; Haeberle, L; Ekici, AB; Beckmann, MW; Brenner, H; Dieffenbach, AK; Arndt, V; Stegmaier, C; Swerdlow, AJ; Ashworth, A; Orr, N; Jones, M; Figueroa, J; Garcia-Closas, M; Brinton, L; Lissowska, J; Dumont, M; Winqvist, R; Pylkäs, K; Jukkola-Vuorinen, A; Grip, M; Brauch, H; Brüning, T; Ko, Y-D; Peterlongo, P; Manoukian, S; Bonanni, B; Radice, P; Bogdanova, N; Antonenkova, N; Dörk, T; Mannermaa, A; Kataja, V; Kosma, V-M; Hartikainen, JM; Devilee, P; Seynaeve, C; Van Asperen, CJ; Jakubowska, A; Lubiński, J; Jaworska-Bieniek, K; Durda, K; Hamann, U; Torres, D; Schmutzler, RK; Neuhausen, SL; Anton-Culver, H; Kristensen, VN; Grenaker Alnæs, GI; DRIVE Project; Pierce, BL; Kraft, P; Peters, U; Lindstrom, S; Seminara, D; Burgess, S; Ahsan, H; Whittemore, AS; John, EM; Gammon, MD; Malone, KE; Tessier, DC; Vincent, D; Bacot, F; Luccarini, C; Baynes, C; Ahmed, S; Maranian, M; Healey, CS; González-Neira, A; Pita, G; Alonso, MR; Álvarez, N; Herrero, D; Pharoah, PDP; Simard, J; Hall, P; Hunter, DJ; Easton, DF; Zheng, W (2015-11)
      Epidemiological studies have linked adult height with breast cancer risk in women. However, the magnitude of the association, particularly by subtypes of breast cancer, has not been established. Furthermore, the mechanisms ...

    • Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. 

      Lophatananon, A; Stewart-Brown, S; Kote-Jarai, Z; Olama, AAA; Garcia, SB; Neal, DE; Hamdy, FC; Donovan, JL; Giles, GG; Fitzgerald, LM; Southey, MC; Pharoah, P; Pashayan, N; Gronberg, H; Wiklund, F; Aly, M; Stanford, JL; Brenner, H; Dieffenbach, AK; Arndt, V; Park, JY; Lin, H-Y; Sellers, T; Slavov, C; Kaneva, R; Mitev, V; Batra, J; Spurdle, A; Clements, JA; APCB BioResource; PRACTICAL consortium; Easton, D; Eeles, RA; Muir, K (2017-08)
      BACKGROUND:Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer. METHODS:We analysed ...

    • Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. 

      Vogelzang, NJ; Coleman, RE; Michalski, JM; Nilsson, S; O'Sullivan, JM; Parker, C; Widmark, A; Thuresson, M; Xu, L; Germino, J; Sartor, O (2017-02)
      BACKGROUND:Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding ...

    • Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. 

      Vogelzang, NJ; Coleman, RE; Michalski, JM; Nilsson, S; O'Sullivan, JM; Parker, C; Widmark, A; Thuresson, M; Xu, L; Germino, J; Sartor, O (2016-08-08)
      Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding risk ...

    • Hepatic DNA adduct dosimetry in rats fed tamoxifen: a comparison of methods 

      Schild, LJ; Phillips, DH; Osborne, MR; Hewer, A; Beland, FA; Churchwell, MI; Brown, K; Gaskell, M; Wright, E; Poirier, MC (OXFORD UNIV PRESS, 2005-03)
      Liver homogenates from rats fed tamoxifen (TAM) in the diet were shared among four different laboratories. TAM-DNA adducts were assayed by high pressure liquid chromatography-electrospray tandem mass spectrometry ...

    • HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2 

      Bartlett, JMS; Ahmed, I; Regan, MM; Sestak, I; Mallon, EA; Dell'Orto, P; Thurlimann, B; Seynaeve, C; Putter, H; Van de Velde, CJH; Brookes, CL; Forbes, JF; Viale, G; Cuzick, J; Dowsett, M; Rea, DW; Inhibitor, TA (2017-07)

    • HER2 status predicts for upfront AI benefit: A TRANS-AIOG meta-analysis of 12,129 patients from ATAC, BIG 1-98 and TEAM with centrally determined HER2. 

      Bartlett, JMS; Ahmed, I; Regan, MM; Sestak, I; Mallon, EA; Dell'Orto, P; Thürlimann, B; Seynaeve, C; Putter, H; Van de Velde, CJH; Brookes, CL; Forbes, JF; Viale, G; Cuzick, J; Dowsett, M; Rea, DW; Translational Aromatase Inhibitor Overview Group (Trans-AIOG) (2017-07)
      A meta-analysis of the effects of HER2 status, specifically within the first 2-3 years of adjuvant endocrine therapy, has the potential to inform patient selection for upfront aromatase inhibitor (AI) therapy or switching ...

    • HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. 

      Martins, CD; Da Pieve, C; Burley, TA; Smith, R; Ciobota, DM; Allott, L; Harrington, KJ; Oyen, WJG; Smith, G; Kramer-Marek, G (2018-04)
      Purpose: Recent studies have highlighted a role of HER3 in HER2-driven cancers (e.g., breast cancer), implicating the upregulation of the receptor in resistance to HER-targeted therapies and Hsp90 inhibitors (e.g., AUY922). ...